Physician profile
Mark Philip Diamond
NPI 1912081019
$6,273.70
in general payments reported to CMS, 2019-2025
62 companies · $762 in 2025
The $762 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,093 · 2020: $718 · 2021: $861 · 2022: $810 · 2023: $947 · 2024: $1,083 · 2025: $762.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,731 · Education: $60.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,731.32 |
| Education | $60.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $483.07 | 2019-2024 | Rinvoq |
| Takeda Pharmaceuticals U.S.A., INC. | $451.92 | 2019-2025 | Iclusig, Entyvio, Alunbrig |
| Janssen Biotech, INC. | $435.11 | 2019-2025 | Carvykti, Tecvayli, Tremfya |
| Pfizer INC. | $344.17 | 2019-2025 | |
| Seagen INC. | $312.16 | 2019-2023 | Adcetris |
| Pharmaessentia USA Corporation | $277.78 | 2022-2025 | Besremi |
| Incyte Corporation | $276.13 | 2019-2023 | Jakafi |
| Amgen INC. | $209.56 | 2019-2022 | |
| Exelixis INC. | $192.75 | 2019-2024 | Cabometyx |
| Eisai INC. | $172.25 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $165.94 | 2019-2025 | Ultomiris |
| Merck Sharp & Dohme LLC | $161.73 | 2019-2024 | Keytruda |
| Agios Pharmaceuticals, INC. | $156.70 | 2019-2025 | Pyrukynd |
| Coherus Oncology, INC. | $152.22 | 2020-2024 | |
| Allergan, INC. | $139.10 | 2019 |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Diamond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.